| Position | Action |
|---|---|
| Current position with ~30% rally off March lows; fwd PE 14.19x is 18-30% above 10-yr norm, P/B 2.64x is 47-76% above norm | Trim ~30% of existing JPM exposure into $355-360 retest |
| Hold remaining ~70% core position | Retain with structural stop at $329 (50 SMA/BB lower band confluence) |
| Confirmed breakout above $359.30 on volume >8M with MACD turning positive | Re-enter reduced position |
| Price pullback to $309-327 with RSI reset and MACD bullish crossover confirmation | Re-enter reduced position |
JPMorgan Chase is built to keep winning due to record-breaking fundamentals, NII tailwinds from higher-for-longer rates, and a widening competitive moat that justifies premium valuation at 17.79% ROE versus 10-12% peer average.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 309.30 | bullish |
| close_50_sma | 326.83 | bullish |
| close_10_ema | 349.16 | neutral |
| macd | 7.04 (signal: 7.33) | bearish |
| macdh | -0.29 | bearish |
| rsi | 60.71 | neutral |
| boll_ub | 359.28 | bearish |
| atr | 7.43 | — |
Support: 349.16 · 344.22 · 329.16 · 326.83 · 309.3 | Resistance: 359.28 · 360
JPM is in a structurally bullish position with a confirmed golden cross (50 SMA $326.83 > 200 SMA $309.30), trading ~13.7% above its 200-day average. Short-term momentum has just turned over: the MACD line ($7.04) crossed below its signal line ($7.33) with histogram negative at -$0.29, and RSI has cooled from overbought (71.1 on 7/28 to 60.7). Price was rejected at the upper Bollinger Band ($359.28) on 7/28 and is now consolidating after a -3.5% reversal day. Recommended action is HOLD for existing holders, with disciplined entries on pullbacks to $344-349 (BB middle/10 EMA zone) or confirmed breakouts above $359.28 on volume > 8M shares.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight JPM: Trim 30% to lock gains, hold 70% with $329 structural stop, re-enter at $309-327 or $359.30 breakout
The Underweight rating reflects the asymmetric risk from peak relative valuation (fwd PE 14.19x, P/B 2.64x) combined with confirmed momentum deterioration (MACD bearish crossover 7.04<7.33, RSI negative divergence at July highs, BB rejection at $359.30 followed by -3.5% reversal on 8.26M volume). The trade setup offers 2.1% upside to $359.30 vs 7.1% downside to $326.83 and 12.1% to $309.30. The $344.22 stop (BB middle band) is a momentum scalp stop that will get shaken out on normal 1.5-3x ATR volatility; the structural stop belongs at $329 where the uptrend is genuinely broken. Underweight respects both truths: the franchise quality is real (17.79% ROE, ~$50B annualized capital return, 5% effective yield, dominant IPO franchise), but the entry point is wrong and multiple compression risk is asymmetric to the downside.
When: Break above $359.30 on volume >8M with MACD turning positive
Then: Re-enter core position
· concedes: Bear's MACD bearish crossover and RSI negative divergence are real but represent healthy momentum normalization, not regime change; Q4 2025 had a $703M litigation charge that depressed headline EPS to $4.63 (normalized to $5.07); Polymarket prices only 26% probability of JPM hitting $1T by Aug 31 (down 15pp on the week); PEG of 1.69 isn't cheap; Stock is up ~30% in 4.5 months from $276.43 to $359.30
JPM is a great franchise at peak-cycle valuation with technical momentum breaking, asymmetric downside risk, and systemic stress indicators flashing warnings—making the current price too expensive relative to future risk.
· concedes: JPM is a great franchise with genuinely strong fundamentals; Record Q2 NII, EPS, revenue, and net income are real achievements; ROE of 17.79% is genuinely high; Capital return program (5%+ effective shareholder yield) is substantial; JPM's market position and franchise quality are not in question; IPO leadership ($114.1B H1 2026 recovery) is real; CoreWeave deal 'winning' is real, just with worsening economics
→ vs conservative: Hold and wait for $344-349 pullback is not a strategy but a fantasy—the plan shows two prior overbought RSI peaks at 71-72 in June/July both followed by sharp pullbacks, and macro features 19-year high bond yields, hawkish Fed pause, and 72% bank-failure probability
→ vs conservative: The conservative analyst 'identifies every warning signal and then refuses to act on them'—MACD crossover, RSI negative divergence, Bollinger Band rejection all identified yet ending with HOLD is 'intellectual cowardice'
→ vs neutral: The neutral analyst ignores that entry point matters more than thesis—the plan itself states 'the bull case is correct that JPM's fundamentals are best-in-class... the entry point is wrong'
→ vs neutral: Q2 earnings EPS up 47% YoY and record NII are rearview mirror metrics; momentum trading requires looking at next 30-60 days, not last quarter
→ vs neutral: 'Mildly bullish' news flow is institutional buy-side narrative construction, not real positioning—StockTwits unavailable and Reddit silent is a vacuum, not a bullish case
→ vs neutral: Bullish structural stories (NII tailwind, IPO recovery, lead arranger status) are unchanged over 18 months while price action, momentum, and prediction markets are all turning—'you're not investing, you're hoping'
Market Cap
$935.13B
PE Ratio (TTM)
15.08x
Forward PE
14.19x
PEG Ratio
1.69
Price / Book
2.64x
Dividend Yield
1.71%
EPS (TTM)
$23.33
Forward EPS
$24.80
EPS Diluted Q2 2026
$7.70
EPS Diluted Q1 2026
$5.94
EPS Diluted Q4 2025
$4.63
EPS Diluted Q3 2025
$5.07
EPS Diluted Q2 2025
$5.24
Net Income (TTM)
$63.63B
Revenue (TTM)
$186.33B
Profit Margin (TTM)
34.92%
Operating Margin (TTM)
50.39%
Return on Equity (ROE)
17.79%
Return on Assets (ROA)
1.36%
Total Revenue Q2 2026
$49.83B
Net Interest Income Q2 2026
$25.37B
Net Income Q2 2026
$16.49B
Total Revenue Q1 2026
$45.80B
Net Interest Income Q1 2026
$24.99B
Net Income Q1 2026
$13.03B
Total Revenue Q4 2025
$46.43B
Net Interest Income Q4 2025
$23.97B
Net Income Q4 2025
$14.39B
Total Revenue Q3 2025
$44.88B
Net Interest Income Q3 2025
$23.21B
Net Income Q3 2025
$14.99B
Total Revenue Q2 2025
$45.33B
Net Interest Income Q2 2025
$23.27B
Net Income Q2 2025
$14.64B
Pretax Income Q2 2026
$20.48B
Pretax Income Q2 2025
$18.41B
Salaries & Wages Q2 2026
$15.34B
Salaries & Wages Q2 2025
$14.09B
SG&A Q2 2026
$17.28B
SG&A Q2 2025
$15.73B
Effective Tax Rate Q2 2026
~19.5%
Total Assets Q1 2026
$4.90T
Total Liabilities Q1 2026
$4.54T
Total Equity Q1 2026
$364.04B
Common Stock Equity Q1 2026
$343.99B
Long-Term Debt Q1 2026
$448.76B
Cash & Equivalents Q1 2026
$312.14B
Goodwill Q1 2026
$52.71B
Tangible Book Value Q1 2026
$279.70B
Treasury Stock Q1 2025
$140.5B
Treasury Stock Q1 2026
$171.7B
Total Assets Q4 2025
$4.42T
Total Liabilities Q4 2025
$4.06T
Total Equity Q4 2025
$362.44B
Long-Term Debt Q4 2025
$433.97B
Cash & Equivalents Q4 2025
$343.34B
Goodwill Q4 2025
$52.73B
Tangible Book Value Q4 2025
$277.94B
Total Assets Q1 2025
$4.36T
Total Liabilities Q1 2025
$4.01T
Total Equity Q1 2025
$351.42B
Cash & Equivalents Q1 2025
$425.90B
Goodwill Q1 2025
$52.62B
Tangible Book Value Q1 2025
$266.85B
Q4 2025 Unusual Charges
$703M
Q1 2026 Benefit
$223M
Debt Issued Q1 2026
$49.9B
Debt Issued Q1 2025
$29.9B
Investment Purchases Q1 2026
$120.6B
Investment Securities Q1 2026
$1.63T
Investment Securities Q1 2025
$1.31T
Operating CF Q1 2026
-$211,761M
Investing CF Q1 2026
-$217,769M
Financing CF Q1 2026
+$400,677M
Operating CF Q4 2025
+$119,724M
Investing CF Q4 2025
+$46,882M
Financing CF Q4 2025
-$123,557M
Operating CF Q3 2025
-$45,214M
Investing CF Q3 2025
-$21,311M
Financing CF Q3 2025
-$47,773M
Operating CF Q2 2025
+$29,547M
Investing CF Q2 2025
-$173,060M
Financing CF Q2 2025
+$122,804M
Operating CF Q1 2025
-$251,839M
Investing CF Q1 2025
-$118,076M
Financing CF Q1 2025
+$318,059M
Annualized Dividends
~$17B
Quarterly Dividends Paid
~$4.2B
Annualized Buybacks
~$32B
Quarterly Buybacks
~$8B
Annualized Capital Return
~$48-50B
Cumulative Buybacks YoY
~$32B
Beta
0.982
52-Week High
$359.30
52-Week Low
$279.10
50-Day MA
$326.56
200-Day MA
$311.63
Implied Stock Price
~$351.60
Diluted Shares Q2 2026
2.694B
Diluted Shares Q1 2026
2.794B
Strengths
Concerns
JPMorgan Chase delivered a record Q2 2026 with EPS of $7.70 (up 47% YoY), total revenue of $49.83B (up 10% YoY), and net interest income of $25.37B — all quarterly records driven by NII expansion and positive operating leverage (SG&A +9.8% vs. revenue +10%). TTM profitability is exceptional with a 17.79% ROE, 34.92% profit margin, and $63.63B in net income, while the balance sheet remains rock-solid with $364.04B in equity and a CET1 ratio comfortably above regulatory minimums. The bank is executing an aggressive ~$48-50B annualized capital return program (buybacks + dividends), reducing diluted share count from 2.794B to 2.694B over five quarters, and trades at a forward PE of 14.19x — reasonable for a high-ROE franchise, though the stock is near its 52-week high ($359.30) with technical risk of consolidation.